JS212

Phase 2Small molecule

SShanghai Junshi Bioscience Co., Ltd.

JS212 is one of 107 small molecule programs targeting Advanced Malignant Solid Tumours. It is currently in Phase 2.

Indications

Total Trials

Active Trials

106

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Malignant Solid TumoursRecruiting

Advanced Malignant Solid TumorsNot yet recruiting

Esophageal Squamous Cell CarcinomaNot yet recruiting

Lung CancerNot yet recruiting

Advanced Malignant Solid TumoursPreclinical

Recruiting

Advanced Malignant Solid TumorsPhase 2

Not yet recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Not yet recruiting

Lung CancerPhase 2

Not yet recruiting

Competition

Competitive Landscape

206 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 3

33 2

Imfinzi

AstraZeneca

Phase 3

25 3

Opdivo

Bristol-Myers Squibb

Phase 3

20 4

Tagrisso

AstraZeneca

Phase 3

19 5

Beyfortus

BeiGene

Phase 3

10 6

Yervoy

Bristol-Myers Squibb

Phase 3

10 7

Abraxane

Bristol-Myers Squibb

Phase 3

7 8

Imjudo

AstraZeneca

Phase 3

6 9

Tecentriq

Roche

Phase 3

6 10

Alunbrig

Takeda

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Esophageal Squamous Cell Carcinoma

NCT07484724

Q4 2028

Phase 2Not yet recruiting

Advanced Malignant Solid Tumors

NCT07480733

Phase 2Not yet recruiting

Lung Cancer

NCT07309276

PreclinicalRecruiting

Advanced Malignant Solid Tumours

NCT06888830

Clinical

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Not yet recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT07480733·480 enrolled

Lung Cancer1 trial

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Not yet recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT07309276·864 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma

Not yet recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 2·NCT07484724·280 enrolled

Advanced Malignant Solid Tumours1 trial

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Preclinical·NCT06888830·374 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for JS212. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — JS212 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for JS212. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Junshi Bioscience Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Junshi Bioscience Co., Ltd.

JS212

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Q4 2028

Trials by Indication[1]

Advanced Malignant Solid Tumors1 trial

Lung Cancer1 trial

Esophageal Squamous Cell Carcinoma1 trial

Advanced Malignant Solid Tumours1 trial

References

Drug Info

Quick Facts

Related News